Curetis and Axonlab sign multi-market European distribution agreement
(Thomson Reuters ONE) -
Curetis AG /
Curetis and Axonlab sign multi-market European distribution agreement
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
- Axonlab to become exclusive distributor for all Unyvero products in selected
Central and Eastern European countries
Amsterdam, the Netherlands, Holzgerlingen, Germany, and Baden, Switzerland, June
06, 2016 -- Curetis N.V. (the "Company" and, together with Curetis GmbH,
"Curetis"), a developer of next-level molecular diagnostic solutions, and Axon
Lab AG, a service company focusing on medical diagnostics, life science and
software solutions for the healthcare sector, today announced the signing of an
exclusive, three-year distribution agreement for Curetis' Unyvero products in
Central and Eastern European countries, including Austria, the Czech Republic,
Slovakia, Slovenia and Croatia. The agreement also includes contractual minimum
purchase commitments by Axonlab.
Through the partnership, Curetis expands its distribution network by four
additional countries and transfers the commercialization responsibilities for
one of its former direct selling territories (Austria) to Axonlab. The agreement
is part of Curetis' expanded commercial effort in Western Europe and allows the
companies to leverage Curetis' existing installed base in Austria, with Axonlab
acquiring multiple commercially installed Unyvero Systems for cash up-front.
Axonlab will deploy a core team of several dedicated molecular diagnostics
commercial representatives covering these markets. This deployment structure
will ensure optimal resource allocation for Curetis in the region.
Axonlab has dedicated microbiology and molecular diagnostics franchises and
direct offices in each of the countries covered under the agreement, and it is
well positioned to accelerate the commercial launch of Unyvero in the CEE
markets.
Curetis will continue its direct sales programs in its home market of Germany,
as well as in Switzerland, the UK, France and the Benelux region.
"We are excited to partner with Curetis for the commercial distribution of the
Unyvero Platform with all of its current and future Application Cartridges in
several of our core markets in Europe," said Guido Mueller, General Manager
Austria of Axonlab. "We believe that Unyvero offers unique and differentiated
syndromic panels to our customers in hospitals and microbiology laboratories.
This collaboration is expected to be another driver for our future growth here
at Axonlab in the years ahead."
Dr. Achim Plum, Chief Commercial Officer of Curetis N.V., added, "This strategic
commercial distribution agreement for multiple markets in Central and Eastern
Europe makes perfect business sense for Curetis. We expect that the Axonlab
partnership will allow us to accelerate the commercial roll-out of Unyvero
products in smaller markets, such as Austria, while adding several new markets
to our distribution portfolio. Moreover, the agreement allows us to focus our
direct commercial efforts on the largest Western European markets, such as the
UK, France, Benelux and Germany as well as Switzerland, to drive our growth. We
currently have a presence in more than thirty countries, either directly or
through our ten distribution partners. We plan to continue expanding this
worldwide network through the addition of new commercial partners."
Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to
investigational use. The information contained in this communication does not
constitute nor imply an offer to sell or transfer any product, and no product
based on the Curetis Unyvero technology is currently available for sale in the
United States of America or Canada. The analytical and clinical performance
characteristics of any Curetis Unyvero product which may be sold at some future
point in time in the U.S. have not yet been established.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
For further information, please visit www.curetis.com.
About Axonlab
Axonlab is an independent corporation involved in distribution, service,
software, and production activities for customers in medical / diagnostic labs
and the life sciences. With its 25 years of experience, Axonlab stands for the
highest degree of excellence in service and system oriented solutions. The
company has more than 240 employees in Switzerland, Germany, Austria, Belgium,
Czech Republic, Slovenia, and Croatia. Axonlab sees itself as a sustainable
company and an active and reliable partner for hospitals, doctors, private
laboratories, and public and private research.
For more information, visit www.axonlab.com
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment
in the commercial register at district court Stuttgart on March 15, 2016 Curetis
plc (AG) changed its legal form into Curetis Ltd. (GmbH).
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2018076/748979.jpg
20160606_Curetis_PR_EN:
http://hugin.info/171382/R/2018076/748976.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Curetis AG via GlobeNewswire
[HUG#2018076]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Treasury Metals Announces CEO DepartureDatum: 06.06.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 475721
Anzahl Zeichen: 9493
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 304 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis and Axonlab sign multi-market European distribution agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
